应用非氟里昂抛射剂的硫酸沙丁胺醇气雾剂治疗支气管哮喘的随机对照临床试验  

A Muti-center,Randomized,Double-blind,Positive Controlled Clinical Trial of Salbutamol Sulfate MDI without CFC in the Treatment of Asthma

作　　者：罗柱[1] 刘春涛[2] 黄奕江[3] 韩晓雯[4] 孙秀珍[5] 郝青林[6] 

机构地区：[1]四川大学华西医院GCP中心,成都610041 [2]四川大学华西医院呼吸内科,成都610041 [3]海南省人民医院呼吸科,海口570311 [4]河北省人民医院呼吸科,石家庄050051 [5]西安交通大学第二附属医院呼吸科,西安710000 [6]昆明医学院第一附属医院呼吸科,昆明650032

出　　处：《四川大学学报（医学版）》2014年第2期266-269,共4页Journal of Sichuan University(Medical Sciences)

摘　　要：目的评价应用非氟里昂抛射剂的国产硫酸沙丁胺醇气雾剂治疗支气管哮喘疗效与安全性。方法以进口硫酸沙丁胺醇气雾剂为阳性对照药,采用多中心、随机、双盲、阳性药物平行对照试验设计,试验组予以单次吸入国产硫酸沙丁胺醇气雾剂,对照组单次吸入进口硫酸沙丁胺醇气雾剂,观察给药后肺功能及症状评分改善情况。结果两组给药后15min,30min,120min,240min第一秒用力呼气容积(FEV1)较给药前均有改善,FEV1增加绝对值在给药后30min达到最大,各个时间点FEV1改善值和改善率组内比较差异有统计学意义(P<0.05),组间比较均无统计学意义(P>0.05);用力肺活量(FVC)、呼吸困难评分、咳嗽评分、呼气相干音评分等症状体征在用药后各个时间点较用药前均改善且差异有统计学意义(P<0.05),组间比较差异无统计学意义(P>0.05)。两组用药后不良反应率差异无统计学意义(P>0.05),均表现出较好的安全性。结论应用非氟里昂抛射剂的国产硫酸沙丁胺醇气雾剂作为支气管哮喘缓解药物的疗效与安全性均较好。Objective To evaluate the efficacy and safety of domestically produced Salbutamol Sulfate metered dose inhaler （MDI） without chloro-fluro-carbon （CFC） in the treatment of asthmatic patients. Methods A muticenter, randomized, double-blind, positive controlled clinical trial was conducted in asthmatic patients. The participants were randomized divided into trial group treated with domestically produced Salbutamol Sulfate Aerosol MDI （200μg single-dose） and control group treated with imported Salbutamol Sulfate Aerosol MDI （200 μg singledose）. The lung function was measured by spirometry and a scoring questionaire before medications and 15, 30, 120 and 240 min post medications. Results A total of 238 patients were enrolled in the trial. Compared with baselines, the forced expiratory volume in 1 s （FEV1） of the participants in both groups increased significantly 15, 30, 120 and 240 rain after medications （P〈0. 05）. There was no significant difference in the changes of FEV1 between the two groups （P〉0.05）. Similarly, the forced vital capacity （FVC） and asthma symptomatic scores of the participants in both groups improved significantly after administration of medications （P 〈 0.05）. There was no significant difference in the ratio of adverse reactions between the two groups （P〉0.05）. In both groups, drugs were well tolerated. Conclusion The domestically produced Salbutamol Sulfate Aerosol MDI without CFC is effective and safe for treating asthma.

关 键 词：定量吸入气雾剂 抛射剂替代 硫酸沙丁胺醇 多中心临床试验 支气管哮喘 

分 类 号：R562.25[医药卫生—呼吸系统]